UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia

Haematologica (Roma), 2010-07, Vol.95 (7), p.1106-1113

2010

Volltextzugriff (PDF)

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients

Haematologica (Roma), 2017-03, Vol.102 (3), p.552-561

2017

Volltextzugriff (PDF)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Thrombosis and haemostasis, 2023-03, Vol.123 (3), p.317-325

2023

Volltextzugriff (PDF)

Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen

Thrombosis and haemostasis, 2022-02, Vol.122 (2), p.208-215

2022

Volltextzugriff (PDF)

Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations

Thrombosis and haemostasis, 2021-06, Vol.121 (6), p.731-740

2021

Volltextzugriff (PDF)

The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators

Blood reviews, 2023-09, Vol.61, p.101098-101098, Article 101098

2023

Volltextzugriff (PDF)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation

Journal of thrombosis and haemostasis, 2020-12, Vol.18 (12), p.3222-3231

2020

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration

Thrombosis and haemostasis, 2020-10, Vol.120 (10), p.1407-1416

2020

Volltextzugriff (PDF)

Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.974-983

2021

Volltextzugriff (PDF)

A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients

Thrombosis and haemostasis, 2020-05, Vol.120 (5), p.747-757

2020

Volltextzugriff (PDF)

von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients

Thrombosis and haemostasis, 2020-07, Vol.120 (7), p.1056-1065

2020

Volltextzugriff (PDF)

Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study

Thrombosis research, 2024-04, Vol.236, p.4-13

2024

Volltextzugriff (PDF)

Pharmacokinetics and population pharmacokinetics in pediatric oncology

Pediatric blood & cancer, 2020-04, Vol.67 (4), p.e28132-n/a

2020

Volltextzugriff (PDF)

Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response

British journal of haematology, 2021-07, Vol.194 (2), p.423-432

2021

Volltextzugriff (PDF)

Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients

Thrombosis and haemostasis, 2018-04, Vol.47 (4), p.621-629

2018

Volltextzugriff (PDF)

Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-09, Vol.28 (5), p.814-821

2022

Volltextzugriff (PDF)

Peri‐operative desmopressin combined with pharmacokinetic‐guided factor VIII concentrate in non‐severe haemophilia A patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-03, Vol.30 (2), p.355-366

2024

Volltextzugriff (PDF)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation

Blood coagulation & fibrinolysis, 2023-04, Vol.34 (3), p.171-178

2023

Volltextzugriff (PDF)

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-07, Vol.28 (4), p.610-618

2022

Volltextzugriff (PDF)

The association between desmopressin exposure, FVIII response and side effects

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.e506-e509

2021

Volltextzugriff (PDF)

Positioning extended half‐life concentrates for future use: a practical proposal

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-09, Vol.24 (5), p.e369-e372

2018

Volltextzugriff (PDF)

Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study

Thrombosis research, 2017-12, Vol.160, p.76-82

2017

Volltextzugriff (PDF)

Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-11, Vol.25 (6), p.960-968

2019

Volltextzugriff (PDF)

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice

Blood advances, 2021-10, Vol.5 (20), p.4314-4325

2021

Volltextzugriff (PDF)

Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B

Research and practice in thrombosis and haemostasis, 2024-03, Vol.8 (3), p.102397-102397, Article 102397

2024

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen

Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations

The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation

Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration

Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model

A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients

von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients

Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study

Pharmacokinetics and population pharmacokinetics in pediatric oncology

Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response

Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients

Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study

Peri‐operative desmopressin combined with pharmacokinetic‐guided factor VIII concentrate in non‐severe haemophilia A patients

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?

The association between desmopressin exposure, FVIII response and side effects

Positioning extended half‐life concentrates for future use: a practical proposal

Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study

Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice

Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B

Aktive Filter

Suchergebnisse filtern